Hydronopol derivatives as agonists on human ORL1 receptors

Details Hydronopol derivatives as agonists on human ORL1 receptors Hydronopol derivatives as agonists on human ORL1 receptors

2007-07-10

2007-07-10

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S020000

Reexamination Certificate

active

11007255

ABSTRACT:
The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved.The invention relates to compounds of the general formula (1)wherein the symbols have the meanings as given in the description.

REFERENCES:
patent: 2001/0041711 (2001-11-01), Kyle et al.
patent: 2003/0109539 (2003-06-01), Jordan et al.
patent: 0 997 464 (2000-05-01), None
patent: 2000169476 (2000-06-01), None
patent: WO 01/07050 (2001-02-01), None
patent: WO 2004/022558 (2004-03-01), None
Bundgaard, “Novel Chemical Approaches in Prodrug Design,”Drugs of the Future16(5): 443-458 (1991).

Affiliated with

Also associated with

Rating

Hydronopol derivatives as agonists on human ORL1 receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydronopol derivatives as agonists on human ORL1 receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydronopol derivatives as agonists on human ORL1 receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3812525